Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-3,page-paged-3,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • Marinomed Biotech AG signs new agreement for Carragelose in South Korea
    www.marinomed.com
  • RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro
    www.redhillbio.com
  • PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients
    www.adrenomed.com
  • MagForce AG: MagForce USA, Inc. receives Payment Code Approval by the American Medical Association for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
    www.magforce.de
  • AiCuris nominates Madam Therapeutics with its innovative peptide approach to fight AMR as the first winner of the AiCubator Resident Status in 2022 at BIOCOM AMR Conference 2022
    www.aicuris.com
  • Andera Partners to sell its Life Sciences’ portfolio company ReViral to Pfizer
    www.anderapartners.com
  • iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022
    www.iomx.com
  • Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis
    www.abivax.com
  • ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
    www.vigeneron.com
  • Newron announces AGM 2022 results
    www.newron.com